PHAT - NASDAQ
Phathom Pharmaceuticals, Inc.
$9.94
+3.0%Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
At a Glance
Live Snapshotphat
Total Liabilities and Equity
Last Annual Value
259.15M
3-Year CAGR
16%
5-Year CAGR
-3%
10-Year CAGR
76%
Phathom Pharmaceuticals, Inc. Competitors Analysis of Total Liabilities and Equity
| Company | Total Liabilities and Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Phathom Pharmaceuticals, Inc. NASDAQ:PHAT | 259.15M | -14.4% | 6.5% | N/A | |
 AnaptysBio, Inc. NASDAQ:ANAB | 364.39M | -7.0% | -10.7% | 19.3% | |
 Xencor, Inc. NASDAQ:XNCR | 875.50M | -2.8% | 0.9% | 7.4% | |
 Nurix Therapeutics, Inc. NASDAQ:NRIX | 688.13M | 24.6% | 7.6% | N/A | |
 UroGen Pharma Ltd. NASDAQ:URGN | 200.46M | 4.0% | 10.9% | 24.1% | |
 Sana Biotechnology, Inc. NASDAQ:SANA | 416.89M | -9.7% | -18.1% | N/A | |
 BridgeBio Oncology Therapeutics Inc. NASDAQ:BBOT | 448.38M | 1004.4% | 399.4% | N/A | |
 Septerna, Inc. NASDAQ:SEPN | 596.19M | 65.8% | N/A | N/A | |
 Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX | 430.99M | 22.6% | N/A | N/A | |
 Kodiak Sciences Inc. NASDAQ:KOD | 351.53M | -9.8% | -17.2% | 40.0% |
Phathom Pharmaceuticals, Inc. Fair Value Envelope
Related Guides
Continue your PHAT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.